Skip to main content
Caplight Logo









Angiex

Angiex

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://angiex.com/

Last Round

VC Round

Nov 17, 2025

Total Funding Raised

$48.5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Angiex is a biopharmaceutical company that develops vascular-targeted biotherapeutics and nuclear-delivered antibody-drug conjugates for the treatment of solid cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugateADConcologycancer therapeuticssolid tumor treatmenttumor vasculatureclinical trialsdrug discoverytargeted therapybiotechout-licensinginvestigational new drugINDprecision medicinepharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Angiex Comparables

Compare Angiex with similar companies based on industry and business-model similarity.

Angiex comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Adcendo
87%
Adcytherix
81%
Adcentrx Therapeutics
81%

Angiex Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundNov 17, 2025
Series BAug 18, 2021
SeedJul 27, 2017
GrantNov 2, 2016

Key People

Founding team and executive leadership

Jeff Sacher

Chief Financial Officer

Executive Team

Glen Weiss

Chief Medical Officer, Scientific Advisory Board Member

Executive Team

Angiex Investors

Notable investors and investment history

Angiex investors
InvestorRounds
Paulson Investment CompanyVC Round
Presight CapitalSeries B
Starling VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 296% MoM, from 652 to 2.6K.

  • Apr 17, 2026

    Presented in vivo data for AGX101, a cancer therapy candidate.

Recent news

Latest coverage and updates

  • is_developingAug 27, 2026

    Angiex is developing AGX101.

Angiex Filings

Explore SEC and related filing metadata, where available.

Angiex filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Angiex's valuation, stock price, and market status.

Is Angiex a public or private company?

Angiex is a private company.

What is the current stock price of Angiex?

Angiex is a private company with no public stock price. No recent secondary market data is available.

How much is Angiex worth (valuation)?

Valuation information for Angiex is not publicly available.

Can I buy Angiex stock?

Angiex shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Angiex's last funding round?

Angiex's most recent funding round was Series B on August 18, 2021.

Who are the main investors in Angiex?

Key investors in Angiex include Presight Capital.

Will Angiex IPO soon?

No public IPO plans have been announced for Angiex.

How can I track Angiex secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Angiex's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range10
Year Founded2015
Last FundingNov 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?